A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma

Summary

The purpose of this study is to establish a safe and tolerable dose of arlocabtagene autoleucel (BMS-986393) in combinations with alnuctamab, mezigdomide, iberdomide, and elranatamab in participants with relapsed and/or refractory multiple myeloma (RRMM).

Eligibility

Inclusion Criteria:

* History of relapsed and/or refractory multiple myeloma (RRMM) treated with at least 3 (Part 1) or at least 1 but not greater than 3 prior anti-myeloma treatment regimens (Part 2).
* Measurable multiple myeloma (MM) as per International Myeloma Working Group (IMWG).
* Eastern Cooperative Oncology Group performance status of 0-1.

Exclusion Criteria:

* Prior treatment with alnuctamab (Arm A), mezigdomide (Arm B), iberdomide (Arm C), elranatamab (Arm D) or BCMA-targeting therapy (Part 2 Arms A and D).
* Prior treatment with GPRC5D-targeting therapies.
* Other protocol-defined inclusion/exclusion criteria apply.

Conditions2

Interventions5

Locations17 sites

Find trials near these locations

Related trials

• Alnuctamab for Refractory SLE (LATTE Study) — Icahn School of Medicine at Mount Sinai
• A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2) — Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
• A Study Evaluating the Safety, Pharmacokinetics, and Activity of the Combination of Cevostamab and Elranatamab in Participants With Relapsed or Refractory Multiple Myeloma (R/R MM) — Genentech, Inc.
• A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant — Pfizer
• Elranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of Care After D-VRd Induction in Transplant-eligible NDMM Patients — Intergroupe Francophone du Myelome
• Mezigdomide and Elranatamab for Relapsed and/or Refractory Multiple Myeloma — YOUNGIL KOH
• Self-administration of Subcutaneous Elranatamab in the Patients' Homes. — Thomas Lund
• The Norwegian Immunotherapy in Multiple Myeloma Study — St. Olavs Hospital

Browse More Trials